News

H.C. Wainwright & Co. Research Update: “First Cohort Enrollment Completed in CYP-001 Clinical Trial; Reiterate Buy”

Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50

Download Company Update